Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus. It works by prolonging the action of incretin hormones, leading to increased insulin secretion and decreased glucagon secretion, thereby improving glycemic control without significant risk of hypoglycemia.
Reviews
There are no reviews yet.